Subcutaneous IG Therapy FAQs
Can I self-administer XEMBIFY?
Most patients or caregivers can be trained to infuse. However, self-administration should be done only after you go through self-infusion training with a healthcare professional. Your specialty pharmacy will provide nurse support to train you to infuse.
You can ask your healthcare provider questions about self-administration, especially if you need a refresher or if your infusion schedule has recently changed. Learn more about how to infuse XEMBIFY.
After I am trained on self-administration, will I still need to visit my healthcare provider?
Yes. It's important to work with your healthcare provider when receiving SCIG therapy. Regular healthcare provider visits are an important part of getting the most out of treatment. At each visit, your healthcare provider will review your treatment regimen, evaluate your response to treatment, and address any concerns you may have. It's important to bring your Infusion Log Book with you when you visit your healthcare provider.
What equipment do I need to start self-infusing XEMBIFY?
If you receive your product and supplies through a specialty pharmacy, they will provide your supplies for infusing XEMBIFY, including an infusion pump, needle set(s), and tubing. Both your specialty pharmacy nurse and healthcare provider can explain your equipment choices, how to use your supplies (including needle size), and how to infuse XEMBIFY.
You can also access the infusion-related resources included in the XEMBIFY Patient Starter Kit. Learn more about infusion resources.
How many infusion sites should be used?
XEMBIFY may be given in 1 to 6 infusion sites with guidance from a healthcare provider. Most patients in the XEMBIFY clinical trials used 4, although fewer may also be used.
Are other resources available to help me with my infusions?
For additional information about infusing XEMBIFY, a dedicated team is ready to answer your questions. Contact Xembify Connexions at: 1-844-MYXEMBIFY (1-844-699-3624) Monday through Friday, 8 AM to 8 PM ET. Learn more about what is available through Xembify Connexions or contact your specialty pharmacy.
Infusing XEMBIFY
Learn about infusing XEMBIFY with this step-by-step video.
What Is PI?
Understand more about the symptoms of PI and how it's diagnosed.
Resources
Learn how to register for XEMBIFY speaker programs, get educational resources, and find PI patient organizations.
Want to receive information and support from Xembify Connexions™?
What is XEMBIFY®?
XEMBIFY® (immune globulin subcutaneous human–klhw) is a 20% immune globulin used in the treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older.
XEMBIFY is for subcutaneous administration only.
Important Safety Information
WARNING: THROMBOSIS
- Thrombosis (formation of blood clots within blood vessels) may occur with immune globulin products, including XEMBIFY. Before you take XEMBIFY, talk to your doctor if you:
- Are older
- Are sedentary (need to lie down or sit down) for long periods of time
- Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
- Have a permanent intravenous (IV) catheter
- Have hyperviscosity of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
- Have cardiovascular (heart) problems or previous history of stroke
- Thrombosis may occur even if you don't have any risk factors
- If you are at risk of thrombosis, your doctor may prescribe XEMBIFY at the minimum dose and infusion rate. Make sure you drink plenty of fluid before taking XEMBIFY. Make sure your doctor is checking you regularly for signs and symptoms of thrombosis and is checking your blood viscosity if you are at risk of hyperviscosity
Who should not use XEMBIFY?
- XEMBIFY should not be used if you have had a severe allergic reaction to human immune globulin, or if you have been told by a doctor that you are IgA deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product
What are possible serious side effects of XEMBIFY?
- Hypersensitivity. Severe allergic reactions may occur with immune globulin products, including XEMBIFY. If you have a severe allergic reaction, stop the infusion immediately and get medical attention. XEMBIFY contains IgA. If you have known antibodies to IgA, you may have a greater risk of developing potentially severe allergic reactions
- Aseptic meningitis syndrome (AMS). Aseptic meningitis is a non-infectious inflammation of the membranes that cover the brain. It causes a severe headache syndrome, which may occur with human immune globulin treatment, including XEMBIFY. If you are showing signs and symptoms of AMS, your doctor may conduct a thorough neurological evaluation including spinal tap (sampling fluid which surrounds the spinal cord) to rule out other causes of meningitis. Stopping human immune globulin treatment has resulted in the end of signs and symptoms within several days. Treatment may include analgesics (pain medicines) and/or a special procedure known as a "blood patch" to stop headache
- Kidney problems or failure. Kidney problems or failure may occur with use of human immune globulin products, especially those containing sucrose (sugar). XEMBIFY does not contain sucrose. If you have kidney disease or diabetes with kidney involvement, your doctor should perform a blood test to assess your hydration level and kidney function before beginning immune globulin treatment and at appropriate intervals thereafter. If your doctor determines that kidney function is worsening, they may discontinue treatment
- Hemolysis. Your doctor should monitor you for symptoms of hemolysis (destruction of red blood cells causing anemia, or low red blood cell count). If your doctor suspects hemolysis, they should perform additional tests to confirm
- Transfusion-related acute lung injury (TRALI). TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress following transfusion. If your doctor suspects TRALI, they will monitor you for any other lung issues. TRALI may be managed with oxygen therapy
- Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases or CJD have been associated with the use of XEMBIFY
- Interference with lab tests. Because XEMBIFY contains a variety of antibodies, blood tests to determine antibody levels may be falsely elevated. Be sure to tell your doctor or lab technician that you are using XEMBIFY
What are other possible side effects of XEMBIFY?
- In clinical studies of XEMBIFY, some patients experienced local side effects (at the injection site) including pain, redness, puffiness, bruising, nodules, itching, firmness, scabbing and swelling at the site on the skin where the injection occurred. Some patients experienced non-injection-site side effects including cough and diarrhea.
- Use of XEMBIFY may interfere with the immune response to virus vaccines, such as vaccines for measles, mumps, rubella and varicella. Tell your doctor you are taking XEMBIFY before getting vaccinations
Please see full Prescribing Information for XEMBIFY.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Terms to Know
PI, primary humoral immunodeficiency disease
SCIG, subcutaneous immune globulin